Genentech Expects To Miss Enbrel Manufacturing Deadlines; Amgen Will Not Reimburse Equipment
This article was originally published in The Pink Sheet Daily
Executive Summary
A Genentech SEC filing notes that milestones such as FDA approval of the manufacturing process would not be met in the agreed upon timeline.